Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Treatment of Widespread Eosinophilic Cellulitis (Wells' Syndrome) with Benralizumab

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Anti-interleukin-17 Treatment on Haemoglobin A1c Levels

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Occupational Skin Cancer in a Crematory Operator

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Disease Mechanisms in Atopic Dermatitis: A Review of Aetiological Factors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prenatal, infantile, and childhood tobacco exposure and risk of pediatric psoriasis in the Danish National Birth Cohort offspring

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Treatment of Widespread Eosinophilic Cellulitis (Wells' Syndrome) with Benralizumab

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Spatially and cell-type resolved quantitative proteomic atlas of healthy human skin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The initiation and evaluation of treatment with biologics for psoriasis is based on the Psoriasis Area Severity Index (PASI) and/or Dermatological Life Quality Index (DLQI). However, these indices do not always correlate well, and changes in the DLQI do not always follow changes in the PASI. Based on data from the Danish national registry (DERMBIO), this study investigated the correlation between changes in PASI and DLQI in a cohort of patients with moderate-to-severe psoriasis treated with biologics or apremilast using Spearman's rank correlation analyses. The correlation analysis of 1,677 patients, of whom 276 had available data after 5 years, showed weak-to-moderate correlation between PASI and DLQI during a 5-year period and between changes in PASI and DLQI: 0.58 (p < 0.0001) for baseline to 3 months and 0.42 (p < 0.0001) for 3 to 12 months. The first question on "Symptoms and feelings" made up the largest proportion of the overall DLQI. The correlation between PASI and DLQI is weak-to-moderate and varies over time. Changes in PASI correlate weak-to-moderately with changes in DLQI during the first 12 months of treatment, with symptoms being the most important factor contributing to impaired quality of life.

OriginalsprogEngelsk
TidsskriftActa Dermato-Venereologica
Vol/bind99
Udgave nummer13
Sider (fra-til)1224-1230
Antal sider7
ISSN0001-5555
DOI
StatusUdgivet - 1 dec. 2019

ID: 58983254